Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727666 | 0.84 | CYP2D6 (0.44) | CYP1A2CYP2C9CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL1734834 | 0.78 | CHRM2 (0.35) | — | |
| SCHEMBL30445486 | 0.71 | HSD17B10 (0.33) | HSD17B10CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL3685302 | 0.71 | HSD17B10 (0.33) | HSD17B10CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL3000347 | 0.71 | — | — | |
| SCHEMBL726031 | 0.70 | CHRM2 (0.42) | — | |
| SCHEMBL14949937 | 0.70 | BACE1 (0.34) | CYP1A2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3005857 | 0.69 | FAAH (0.32) | — | |
| Phenanthrene SCHEMBL28522812 | 0.68 | ALDH1A1 (0.67) | HSD17B10CYP1A2CYP2D6ALDH1A1CYP2A6 | |
| SCHEMBL1734019 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527038-B1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | LUCITE INT UK LTD (GB) | 2010-03-17 | — | — | EP | claimed |
| US-20080051475-A1 | Process for the Hydroformylation of Ethylenically Unsaturated Compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-02-28 | — | — | US | claimed |
| US-7371705-B2 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | ADORA2A, ADORA3, ADGRE5 | HSD17B10 1997/4885CYP1A2 252/4885CYP2C9 1206/4885 |
| US-20080051475-A1 | Process for the Hydroformylation of Ethylenically Unsaturated Compounds | ETV6, DHPS, ELOVL6 | HSD17B10 1005/4885CYP1A2 883/4885CYP2C9 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.